Welcome to our dedicated page for Seqll news (Ticker: SQLLW), a resource for investors and traders seeking the latest updates and insights on Seqll stock.
Seqll Inc (SQLLW) delivers cutting-edge true single molecule sequencing solutions for advanced genomic research while expanding into strategic operational services. This news hub provides investors and researchers with essential updates on the company's scientific advancements and business developments.
Access comprehensive coverage of Seqll's financial announcements, technology milestones, and operational expansions. Our curated collection includes earnings reports, partnership announcements, and innovation disclosures directly from corporate communications and verified sources.
Key updates feature RNA/DNA sequencing breakthroughs, helicos SMS technology enhancements, and strategic staffing initiatives. Track regulatory filings, patent developments, and research collaborations that shape the company's trajectory in biotechnology and outsourced services.
Bookmark this page for streamlined access to Seqll's latest press releases and market-moving announcements. For stakeholders requiring timely, accurate information on sequencing innovations and operational strategies, this resource serves as your primary reference for informed decision-making.
Atlantic International Corp. (OTC: ATLN), formerly known as SeqLL Inc. (OTC: SQL), has announced the acquisition of Lyneer Staffing Solutions. This strategic move creates a national staffing and workforce solutions company with annual revenues exceeding $400 million and an adjusted EBITDA of $5.4 million as of December 31, 2023. The acquisition involves a $35 million promissory note and $60 million in restricted stock. Lyneer serves over 1,100 customers, including major companies like UPS, DHL, FedEx, and PepsiCo. The CEO of Atlantic, Jeffrey Jagid, aims to leverage this acquisition for strategic growth, focusing on medical, IT, and engineering staffing. Additionally, Prateek Gattani of IDC Technologies, the principal shareholder, has been appointed Chairman. The company aims to uplist to a National Securities Exchange soon.
SeqLL Inc. (NASDAQ: SQL; SQLLW) reported its financial results for the year ended December 31, 2022, indicating total revenues of $0.079 million, down 63% from $0.21 million in 2021. Gross profits also decreased by 49%, totaling $0.078 million. Research and development expenses surged 196% to $1.57 million, reflecting a return to pre-pandemic activity levels. General and administrative expenses rose 15% to $2.5 million. The net loss for the year increased by 11% to $4.09 million. Cash, cash equivalents, and investments amounted to $6.2 million as of year-end.
SeqLL Inc. (Nasdaq: SQL, SQLLW) has successfully completed a registered direct offering of 2,000,000 shares of common stock at $0.90 per share, raising approximately $1.8 million in gross proceeds. The offering, facilitated by Maxim Group LLC, is part of the company's ongoing strategy to enhance its life sciences instrumentation and research services. The shares were issued under the company's shelf registration statement filed with the SEC. This financing will support SeqLL's development of its True Single Molecule Sequencing platform, aimed at advancing genomic medicine.
SeqLL Inc. (NASDAQ: SQL, SQLLW) announced a securities purchase agreement with institutional investors to sell 2,000,000 shares of common stock at $0.90 per share in a registered direct offering, generating approximately $1.8 million in gross proceeds. The offering is managed by Maxim Group LLC and is expected to close by February 15, 2023, subject to customary conditions. The shares are being offered under a shelf registration statement declared effective by the SEC. SeqLL specializes in life sciences instrumentation and research services, focusing on the development of innovative solutions in genomics.
SeqLL Inc. (NASDAQ: SQLLW) received a 180-day extension from Nasdaq to meet the $1.00 minimum bid price requirement, with a new compliance deadline set for June 19, 2023. The extension was granted due to the company satisfying other listing requirements. If the share price closes above $1.00 for 10 consecutive trading days, compliance will be regained. If not, SeqLL may face delisting but can appeal the decision. Meanwhile, it plans to monitor the stock price and may consider a reverse stock split.
FAQ
What is the current stock price of Seqll (SQLLW)?
